About Endo Barrier
a US based company, is in the process of developing a
device called EndoBarrier which is fundamentally a gastrointestinal impermeable barrier or a gastric sleeve
prevents food from coming in contact with the intestinal wall.
to Bariatric Surgery Chief Keith Gersin, M.D., at Carolinas Medical Center in
Charlotte, N.C., "Endobarrier is a sleeve that is placed without surgery
into the patient's small intestine to help them achieve weight loss."
device is implanted endoscopically through the mouth and is placed in such a
way that it lines the first two feet of the small intestine. This helps to
prevent easy absorption of food as long as it remains in the sleeve and has
huge impact on the person's intake of nutrients and calories.
EndoBarrier is implanted and removed endoscopically.
implantation can be carried out as a day procedure
overall metabolic effect that results from the implantation of the device is
similar to the complicated Roux-en-Y gastric bypass surgical procedure in that
it helps to resolve type 2 diabetes and bring about weight loss
is reversible unlike some of the other bariatric surgical procedures
Currently the device is being considered as a prelude to gastric
bypass surgery and hence is treated as a temporary fix. But, according to Dr. Gersin its future, as a
non-surgical alternative to weight loss treatment, is extremely promising.
A pilot clinical trial, conducted by GI Dynamics on
patients with uncontrolled type 2 diabetes, who had the Endo Barrier device
implanted in them, revealed a "statistically significant improvement of
glycemic control in just one week as compared to a sham control."
experimental studies have also revealed that individuals who harbor the device
had more weight loss when compared to those with no endobarrier.
control in Type 2 diabetes
alternative to gastric bypass
GI Dynamics is looking at the exciting prospects of employing
EndoBarrier in the treatment of
obesity and type 2 diabetes. Of course they are vying at a world wide market,
as millions of people could benefit from this potential mode of treatment.
Clinical trial -Highlights
study data reveal that EndoBarrier patients experienced a mean reduction in the
levels of HbA1c glucose
supports the initial findings announced in June at the American Diabetes
Association annual meeting that the EndoBarrier rapidly improves glycemic control
in type 2 diabetics within a week, irrespective of weight loss.
effect of EndoBarrier compared favorably to the current high-impact diabetes
Most patients with the device experienced a
substantial 51.6 point reduction of fasting blood glucose levels (another major
indicator of diabetes) by one week
Some of these
patients were able to stop taking their medication as their blood sugar levels
patients reported an average weight loss upto 27.5 lb by week 30.
Dr. Reeja Tharu/L